Endometrial cancer, types, prognosis, female hormones and antihormones

Climacteric

Volumn 14, Issue 4, 2011, Pages 418-425

  Ulrich, L S G ^a  

^a Rigshospitalet   (Denmark)

Author keywords

Cancer; Endometrium; Estrogen; Progestogen; Tamoxifen

Indexed keywords

BRCA2 PROTEIN; ESTROGEN; GESTAGEN; HYDROXYPROGESTERONE; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; PROTEIN P53; TAMOXIFEN; TIBOLONE;

BODY MASS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASE CONTROL STUDY; CLINICAL EFFECTIVENESS; DEVICE REMOVAL; DRUG MEGADOSE; ENDOMETRIUM BIOPSY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FOLLOW UP; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; LOW DRUG DOSE; METRORRHAGIA; MULTICENTER STUDY (TOPIC); OBESITY; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TUMOR SUPPRESSOR GENE; UNSPECIFIED SIDE EFFECT;

BODY MASS INDEX; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HORMONE ANTAGONISTS; HORMONES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; PROGNOSIS; RISK FACTORS; UTERINE HEMORRHAGE;

EID: 79960443601     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2010.550974     Document Type: Review

References (83)

1. http://globocan.iarc.fr/summary-table-site.asp?selection6162& titleCorpus\+uteri&sex2&type0&window1&africa1&america2& asia3&europe4&oceania5&build6&sort0&submit%A0Execute%A0
2. Mariani A, Dowdy SC, Podratz KC. New surgical staging of endometrial cancer: 20 years later. Int J Gynecol Obstet 2009;105:110-11
3. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. In 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynecol Obstet 2006;95 (Suppl 1):S105-43
4. Hamilton CA, Cheung MK, Osann K, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 2006;94:642-6 (Pubitemid 43361894)
5. Horn LC, Meinel A, Handzel R, et al. Histopathology of endometrial hyperplasia and endometrial carcinoma. An update. Ann Diagnostic Pathol 2007;11:297-311 (Pubitemid 47043499)
6. Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet 2005;366:491-505 (Pubitemid 41111699)
7. Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 1987;60:2035-41 (Pubitemid 17145924)
8. Chi DS, Barakat RR, Palayekar MJ, et al. The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer 2008;18:269-73 (Pubitemid 351365228)
9. Mariani A, Dowdy SC, Cliby WA, et al. Prospective assessment of lymphatic dissemination in endometrial cancer: A paradigm shift in surgical staging. Gynecol Oncol 2008;109:11-18
10. Cirisano Jr FD, Robboy SJ, Dodge RK, et al. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 2000;77:55-65 (Pubitemid 30217305)
11. Chia VM, Newcomb PA, Trentham-Dietz A, et al. Obesity, diabetes, and other factors in relation to survival after endome-trial cancer diagnosis. Int J Gynecol Cancer 2007;17:441-6 (Pubitemid 46426761)
12. Salvesen HB, Carter SL, Mannelqviste M, et al. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proc Natl Acad Sci USA 2009;106:4834-9
13. Gredmark T, Kvint S, Havel G, et al. Histopathological findings in women with postmenopausal bleeding. Br J Obstet Gynaecol 1995;102:133-6
14. The Danish Gynecological Cancer Database Yearly Report 2008. http://dgc.eu.com/
15. Goldstein SR. The role of transvaginal ultrasound or endometrial biopsy in the evaluation of the menopausal endometrium. Am J Obstet Gynecol 2009;201:5-11
16. Van Den Bosch T, Van Schoubroeck D, Domali E. A thin and regular endometrium on ultrasound is very unlikely in patients with endometrial malignancy. Ultrasound Obstet Gynecol 2007; 29:674-9 (Pubitemid 46975106)
17. Dreisler E, Stampe Sorerensen S, Ibsen PH, et al. Prevalence of endometrial polyps and abnormal uterine bleeding in a Danish population aged 20-74 years. Ultrasound Obstet Gynecol 2009; 33:102-8
18. Lee SC, Kaunitz AM, Sanchez-Ramos L, et al. The oncogenic potential of endometrial polyps. a systematic review and meta-analysis. Obstet Gynecol 2010;116:1197-212
19. Smith-Bindman R, Weiss E, Feldstein V. How thick is too thick? When endometrial thickness should prompt biopsy in postmeno-pausal women without vaginal bleeding. Ultrasound Obstet Gynecol 2004;24:558-65 (Pubitemid 39424681)
20. Sturdee DW, Ulrich LG, Barlow DH, et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. BJOG 2000;107:1392-400
21. Danish Gynecological Cancer Group guidelines. Retningslinier for visitation, diagnostik, behandling og kontrol af cancer corporis uteri 08.12.2009 http://dgc.eu.com/fundanemt/files/filer/Corpuscancer/ Endometriecancer-2010-jan
22. McCullough ML, Patel AV, Patel R, et al. Body mass and endometrial cancer risk by hormone replacement therapy and cancer subtype. Cancer Epidemiol Biomarkers Prev 2008;17:73-9 (Pubitemid 351196275)
23. Pickard JH, Yeh I-T, Wheeler JE, et al. Endometrial effects of lower doses of conjugated equine estrogens and medroxyproges-terone acetate: two-year substudy results. Fertil Steril 2003;80:1234-40 (Pubitemid 37377757)
24. Sherman AI, Brown S. The precursers of endometrial carcinoma. Am J Obstet Gynecol 1979;135:947-56
25. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endome-trial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403-12 (Pubitemid 15031667)
26. Baak JP, Wisse-Brekelmans EC, Fleege JC, et al. Assessment of the risk of endometrial cancer in hyperplasia, by means of morphological and morphometrical features. Pathol Res Pract 1992;188:856-9
27. Terakawa N, Kigawa J, Taketani Y, et al. The behavior of endometrial hyperplasia: a prospective study: Endometrial Hyper-plasia Study Group. J Obstet Gynaecol Res 1997;23:223-30 (Pubitemid 27292475)
28. Ørbo A, Baak LPA, Kleivan I, et al. Comuterized morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long term retrospective study from northern Norway. J Clin Pathol 2000;53:697-703
29. Tabata T, Yamawaki T, Yabana T, et al. Natural history of endometrial hyperplasia. Arch Gynecol Obstet 2001;265:85-8
30. Horn L-C, Schnurrbusch U, Bilek K, et al. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer 2004;14:348-53 (Pubitemid 38533908)
31. Baak JP, Mutter GL, Robboy S, et al. The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer 2005;103:2304-12 (Pubitemid 40686575)
32. Lacey JV Jr, Ioffe OB, Ronnett BM, et al. Endometrial carcinoma risk among women diagnosed with endometrial hyperplasia: the 34-year experience in a large health plan. Br J Cancer 2008;98: 45-53
33. Lacey JV Jr, Sherman ME, Rush BB. Absolute risk of endometrial carcinoma during 20-year follow-up among women with en-dometrial hyperplasia. J Clin Oncol 2010;28:788-92
34. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without proges-tins. J Natl Cancer Inst 1999;91:1131-7 (Pubitemid 29330551)
35. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304
36. Shapiro S, Kelly JP, Rosenberg L, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985; 313:969-72 (Pubitemid 15250215)
37. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy. Scientific review. JAMA 2002; 288:872-81
38. Weiderpass E, Baron JA, Adami HO, et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 1999;353:1824-8 (Pubitemid 29251013)
39. Ulrich LSG, Naessen T, Elia D, et al. Endometrial safety of ultra-low-dose Vagifem 10 mg in postmenopausal women with vaginal atrophy. Climacteric 2010;13:228-37
40. Pukkala E, Tulenheimo-Silfvast A, Leminen A. Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997. Cancer Causes Control 2001;12:111-15 (Pubitemid 32165268)
41. Bjarnason K, Cerin A, Lindgren R, et al. The Scandinavian Long Cycle Study Group. Adverse endometrial effects during long cycle hormone replacement therapy. Maturitas 1999;32:161-70 (Pubitemid 29389731)
42. Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110-16 (Pubitemid 27337924)
43. Beresford SAA, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349:458-61 (Pubitemid 27077825)
44. Wells M, Sturdee DW, Barlow DH, et al. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study. Br Med J 2002;325:239-42 (Pubitemid 34868000)
45. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321-33
46. Heiss G, Wallace R, Anderson GL. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008;299:1036-45 (Pubitemid 351347060)
47. The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12
48. Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51
49. de Vries CS, Bromley SE, Thomas H, et al. Tibolone and endometrial cancer. a cohort and nested case-control study in the UK. Drug Safety 2005;28:241-9 (Pubitemid 40364890)
50. Langer RD, Landgren BM, Rymer J, Helmond FA for the OPAL Investigators. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL Study. Am J Obstet Gynecol 2006;195:1320-7 (Pubitemid 44740410)
51. Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:911-18 (Pubitemid 46465662)
52. Bergman L, Beelen MLR, Gallee MPW, et al., the Comprehensive Cancer Centres ALERT Group. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000;356:881-7
53. Wilder JL, Shajahan S, Khattar NH. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-alfa, estrogen-beta and progesterone; a case controlled study. Gynecol Oncol 2004;92:553-8 (Pubitemid 38183144)
54. Cohen I, Perel E, Flex D, et al. Endometrial pathology in postmenopausal tamoxifen treatment: comparison between gy-naecologically symptomatic and asymptomatic breast cancer patients. J Clin Pathol 1999;52:278-82 (Pubitemid 29161491)
55. Swain SM. Aromatase inhibitors-a triumph of translational oncology. N Engl J Med 2005;353:2807-9 (Pubitemid 43016822)
56. Doherty JA, Cushing-Haugen KL, Saltzman BS, et al. Long-term use of postmenopausal estrogen and progestin hormone therapies and the risk of endometrial cancer. Am J Obstet Gynecol 2007;197:139.e1-139.e7
57. Reeves GK, Pirie K, Beral V, et al. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study. BMJ 2007;335:1134-9 (Pubitemid 350247286)
58. Chubak J, Doherty JA, Cushing-Haugen KL, et al. Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy. Cancer Causes Control 2007;18:1001-7 (Pubitemid 47237961)
59. Lindahl B, Alm P, Ferno M, et al. Endometrial hyperplasia: a prospective randomized study of histopathology, tissue steroid receptors and plasma steroids after abrasio, with and without high dose gestagen treatment. Anticancer Res 1990;10:725-30 (Pubitemid 20237824)
60. Reed SD, Voigt LF, Newton KM, et al. Progestin therapy of complex endometrial hyperplasia with and without atypia. Obstet Gynecol 2009;113:655-62
61. Clark TJ, Neelakantan D, Gupta JK. The management of endometrial hyperplasia: an evaluation of current practice. Eur J Obstet Gynecol Reprod Biol 2006;125:259-64
62. Wildemeersch D, Janssens D, Pylyser K, et al. Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel- releasing intrauterine system: long-term follow-up. Maturitas 2007;57:210-13 (Pubitemid 46771029)
63. Wheeler DT, Bristow RE, Kurman RJ. Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 2007;31:988-98 (Pubitemid 47012294)
64. Haimovich S, Checa MA, Mancebo G, Fusté P, Carreras R. Treatment of endometrial hyperplasia without atypia in peri-and postmenopausal women with a levonorgestrel intrauterine device. Menopause 2008;15:1002-4
65. Varma R, Soneja H, Bhatia K, et al. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-a long-term follow-up study. Eur J Obstet Gynecol Reprod Biol 2008;139:169-75
66. Vereide AB, Kaino T, Sager G, Arnes M, Ørbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol 2006;101:214-23
67. Ørbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol 2008;111:68-73
68. Buttini MJ, Jordan SJ, Webb PM. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. Aust NZ J Obstet Gynaecol 2009;49:316-22
69. Martin-Hirsch PPL, Jarvis GG, Kitchener HC, Lilford R. Progestagens for endometrial cancer. Cochrane Database of Systematic Reviews 1999;Issue 4. Art. No.: CD001040
70. Jadoul P, Donnez J. Conservative treatment may be beneficial for young women with atypical endometrial hyperplasia or endome-trial adenocarcinoma. Fertil Steril 2003;80:1315-24 (Pubitemid 37532439)
71. Niwa K, Tagami K, Lian Z, et al. Outcome of fertility-preserving treatment in young women with endometrial carcinomas. BJOG 2005;112:317-20 (Pubitemid 40314007)
72. Ushijima K, Yahata H, Yoshikawa H, et al. Multicenter phase ii study of fertility-sparing treatment with medroxyprogesterone acetate for endometrial carcinoma and atypical hyperplasia in young women. J Clin Oncol 2007;25:2798-803 (Pubitemid 47123189)
73. Walsh C, Holschneider C, Hoang Y, et al. Coexisting ovarian malignancy in young women with endometrial cancer. Obstet Gynecol 2005;106:693-9 (Pubitemid 41362170)
74. Gitsch G, Hanzal E, Jensen D, Hacker NF. Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 1995;85:504-8
75. Shamshirsaz AA, Withiam-Leitch M, Odunsi K, et al. Youngpatients with endometrial carcinoma selected for conservative treatment: a need for vigilance for synchronous ovarian carcinomas, case report and literature review. Gynecol Oncol 2007;104:757-60 (Pubitemid 46240271)
76. Morice P, Fourchotte V, Sideris L, et al. A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment. Gynecol Oncol 2005;96:245-8 (Pubitemid 39612444)
77. Lee TS, Jung JY, Kim JW, et al. Feasibility of ovarian preservation in patients with early stage endometrial carcinoma. Gynecol Oncol 2007;104:52-7 (Pubitemid 46054111)
78. Wright JD, Buck AM, Burke WM, et al. Safety of ovarian preservation in premenopausal women with endometrial cancer. J Clin Oncol 2009;27:1214-19
79. Tangjitgamol S, Manusirivithaya S, Hanprasertpong J, et al. hormone replacement therapy after treatment of endometrial cancer. Gynecol Obstet Invest 2008;65:35-8
80. Chapman JA, DiSaia PJ, Osann K, et al. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol 1996;175:1195-200 (Pubitemid 26398977)
81. Lee RB, Burke TW, Parke RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 1990;36:189-91 (Pubitemid 20061284)
82. Creasman WT, Henderson D, Hinshaw W, et al. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 1986;67:326-30 (Pubitemid 16129969)
83. Barakat RR, Bundy BN, Spirtos NM, et al. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2006;24:587-92 (Pubitemid 46630420)